Insilico, a China-based AI-focused drug discovery firm has raised $60 million in its Series D funding round.
- The funds will be used to support its Phase I Studies (Clinical trial and safety testing), develop its drug discovery platform, enter international markets, and build a robotic drug discovery lab and a robotic biological data factory.
- The firm provides drug discovery services since it launched and is now offering therapeutics in fibrosis, immunology, oncology, and the central nervous system, with eight candidates nominated so far.
- It last raised $255 million in its Series C a year ago.
- Warburg Pincus, B Capital, Qiming Venture Partners, BOLD Capital Partners, and Pavilion Capital participated in the new funding round.